MCHP · Q1 2026 Earnings
BullishMicrochip Technology
Reported August 7, 2025
30-second summary
Microchip posted $1.08B in Q1 FY26 revenue, down 13.4% YoY but up 10.8% sequentially — the first real evidence that the two-year analog/MCU correction has bottomed. Management guided September to $1.13B (+5.1% QoQ) with gross margin stepping to 55–57% from 54.3%, and explicitly told investors the company will stop borrowing to fund the dividend after this quarter. Tone has shifted from defensive restructuring to quantifying the recovery mechanics — 77% incremental operating profit conversion, lead times bouncing off the bottom, July bookings the highest in three years.
Headline numbers
EPS
Q1 FY2026
$0.27
Revenue
Q1 FY2026
$1.08B
-13.4% YoY
Gross margin
Q1 FY2026
54.3%
Free cash flow
Q1 FY2026
$0.26B
Operating margin
Q1 FY2026
20.7%
Key financials
Q1 FY2026| Metric | Q1 FY2026 | YoY |
|---|---|---|
| Revenue | $1.08B | -13.4% |
| EPS | $0.27 | — |
| Gross margin | 54.3% | — |
| Operating margin | 20.7% | — |
| Free cash flow | $0.26B | — |
Guidance
Prior quarter data unavailable — comparison not possible.
Capacity & utilization
Q1 FY2026| Segment | Q1 FY2026 |
|---|---|
| Inventory Days on Balance Sheet | 214 days |
| Distribution Inventory Days | 29 days |
| Inventory Reduction | $124.4 million |
Profitability
Q1 FY2026| Segment | Q1 FY2026 |
|---|---|
| Non-GAAP Operating Margin | 20.7% |
| Non-GAAP Gross Margin | 54.3% |
| Free Cash Flow Margin | 24.0% |
| Incremental Non-GAAP Gross Margin | 76% |
| Incremental Non-GAAP Operating Margin | 82% |
Management tone
Management's posture has flipped from defensive restructuring narrative to actively quantifying recovery mechanics. Where prior quarters framed the inventory correction as a margin and revenue headwind requiring fab shutdowns and pay cuts, this print reframes the same inventory dynamic as a tailwind: "We are filling a supply chain deficit rather than experiencing any significant pull-forward activity... we expect the increase in gross margin percentage will continue as the inventory write-off continues to decrease." The same operational facts now point upward.
The lead-time commentary marks a clear regime change. For the past several quarters lead times sat stable at 4–8 weeks with ample capacity; this quarter management is openly telling investors that lead times are extending and supply chain capacity is being absorbed. "We are experiencing a lead time bounce off the bottom and increases on some of our products... we expect them to broaden and lead times go from the 4 to 8 weeks range to more like 6 to 10 weeks range." This is the first sign of pricing power returning to the channel, but it also raises the tail risk of repeating the PSP excess-inventory cycle — management addressed this preemptively, distinguishing current "scheduled backlog" requests from the prior non-cancellable PSP program.
Management aggressively rebutted the tariff-pull-in thesis that has dominated peer commentary. Rather than hedge, they quantified: tariff-related pull-ins were "mid to high single-digit millions" — roughly $7–9M of a $1.08B revenue base. This is the kind of specificity management uses when it wants to take a contrarian view off the table for investors, and it directly opposes the cautious framing from analog peers this earnings season.
The capital allocation message shifted from balance-sheet defense to durable capital return. "After this September quarter, we expect our adjusted free cash flow to exceed our dividend payment... we do not expect to have to borrow money to pay our dividend after this quarter." The dividend is no longer in question; excess cash flow goes to debt paydown. That is a meaningfully different message than the one Microchip delivered through the depth of the correction.
The emotional register also shifted. Management led with: "18,000 employees of Microchip worked all last year on a pay cut, have not received a bonus or a salary increase in a year and a half... came together to deliver an outstanding quarter." That is not a sentence a defensive management team writes. It signals confidence that recovery is durable enough to justify reinstating compensation, and quietly flags employee retention risk if recovery were to stall.
Recurring themes management leaned on this quarter:
Risks management surfaced:
Q&A highlights
Chris Cazzo · Wolf Research
How far below end demand is the company shipping now, particularly for direct customers vs. distributors? Can you quantify undershipping?
Management acknowledges undershipping but declines to provide audit-proof numbers, citing data complexity (110,000+ customers, 26 global factories per customer, mixed inventory positions across products). Notes that during 'go-go days' direct customers received disproportionate shipments and likely built higher inventory than distributors, implying greater undershipping to direct customers today.
Blaine Curtis · Jefferies
Are lead time extensions (4-8 weeks to 6-10, 8-12 weeks) current or forward-looking? Why encourage customer orders if concerned about PSP-like dynamics?
Lead times currently extending on certain products/packages (6-10 weeks, some 8-12 weeks) due to lead frame, substrate, and subcontractor constraints. Management clarifies it's requesting scheduled backlog placement (not expediting), with fully cancelable orders and no rule changes—fundamentally different from PSP program. Largest monthly bookings in 3 years in July; backlog started September quarter stronger than June.
Timothy Arcuri · UBS
If bookings are highest in 3 years but guidance is only 5% sequential growth and turns are flat, doesn't this imply bookings are pulling into Q4/December rather than Q3/September? Should December be a 'good quarter'?
Management confirms that July bookings were strong and some portion is flowing into calendar Q4. September backlog is meaningfully higher than June backlog; with similar turns, expects 'good' September quarter (avoided defining 'good' with specific numbers). Reiterates expectation of above-seasonal growth in September, December, and March quarters.
What to watch into next quarter
September gross margin within 55–57% guide range and incremental margin conversion above 70% — the entire bull case rests on operating leverage delivering as factory utilization ramps. A print at the low end with high underutilization charge would undermine the recovery thesis.
Inventory days reaching 195–200 by September quarter-end — management committed to this number explicitly. Slippage above 210 would signal demand is not recovering fast enough to absorb the burn-down pace.
Whether sell-through vs. sell-in gap closes further from $49.3M — convergence toward zero is the cleanest signal that distributor restocking is becoming end-demand-driven.
December guidance magnitude — does management commit to above-seasonal in dollar terms? — Arcuri's question went unanswered with specifics. If December comes in at or below 3% sequential, the "above-seasonal in three consecutive quarters" claim breaks.
Lead times stabilizing or extending beyond 6–10 weeks — extension toward 12+ weeks across broader product lines would raise PSP-repeat risk and likely force management to address speculative ordering directly.
Whether adjusted FCF actually exceeds the dividend in Q2 FY26 as promised — explicit commitment made on this print; the credibility of management's "stop borrowing to fund the dividend" message hinges on Q2 FCF clearing the common dividend run-rate (Q1 returned ~$245.5M to common stockholders via dividends per the press release).
Sources
- Microchip Technology Q1 FY2026 press release, exhibit 99.1, filed via SEC EDGAR — https://www.sec.gov/Archives/edgar/data/827054/000082705425000132/exhibit991q1fy26.htm
- Q&A content drawn from prepared analyst-call exchanges referenced in extraction inputs (Vivek Arya, Harsh Kumar, Chris Cazzo/Wolf Research, Blaine Curtis/Jefferies, Timothy Arcuri/UBS).
Get the next brief, free.
We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.
This is not investment advice.